cisplatin
Showing 1 - 25 of 1,704
Chemo;Advanced Gastric Cancer;Cisplatin;Disulfiram Trial in Hangzhou (disulfiram and cisplatin, cisplatin)
Not yet recruiting
- Chemotherapy;Advanced Gastric Cancer;Cisplatin;Disulfiram
- disulfiram and cisplatin
- cisplatin
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Dec 26, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Strasbourg (Split Cisplatin, Cisplatin, Radiotherapy)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Split Cisplatin
- +2 more
-
Strasbourg, FranceCentre Paul Strauss
Mar 10, 2022
Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic
- KL-A167
- +3 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Mar 23, 2022
Hepatocellular Carcinoma Trial in Hong Kong (Cisplatin)
Recruiting
- Hepatocellular Carcinoma
- Cisplatin
-
Hong Kong, Hong KongDepartment of Imaging and Interventional Radiology, Prince of Wa
Mar 10, 2022
Penile Cancer Trial in Guangzhou (Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin)
Completed
- Penile Cancer
- Albumin-Bound Paclitaxel
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 8, 2022
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable Trial in Scottsdale (Ascorbic Acid, Paclitaxel
Completed
- Pancreatic Cancer
- +4 more
- Ascorbic Acid
- +3 more
-
Scottsdale, ArizonaHonorHealth Research Institute
Feb 10, 2022
Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Cisplatin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 18, 2022
Advanced Biliary Tract Cancer Trial in Guangzhou (Envofolimab, Lenvatinib, Gemcitabine)
Not yet recruiting
- Advanced Biliary Tract Cancer
- Envofolimab
- +3 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Jun 9, 2022
Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)
Recruiting
- Urothelial Carcinoma Bladder
- PD-1 Inhibitor
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022
Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable Trial in Hannover (Durvalumab, Gemcitabine,
Active, not recruiting
- Cholangiocarcinoma
- +3 more
- Durvalumab
- +3 more
-
Hannover, GermanyMedizinische Hochschule Hannover, Klinik für Gastroenterologie,
Oct 14, 2021
Cervical Carcinoma Trial in La Jolla (Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Gemcitabine)
Completed
- Cervical Carcinoma
- Intensity Modulated Radiation Therapy (IMRT)
- +2 more
-
La Jolla, CaliforniaMoores UC San Diego Cancer Center
Feb 16, 2022
Carcinoma, Squamous Cell, Head Neck Cancer Trial in Lexington (Cisplatin, XRT)
Recruiting
- Carcinoma, Squamous Cell
- Head and Neck Cancer
- Cisplatin
- XRT
-
Lexington, KentuckyUniversity of Kentucky
Nov 17, 2021
Adenocarcinoma, Pancreatic Tumors, Tumor, Glandular Trial in Baltimore (Nab-paclitaxel, Gemcitabine, Capecitabine)
Recruiting
- Adenocarcinoma
- +9 more
- Nab-paclitaxel
- +4 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 15, 2022
Head and Neck Squamous Cell Carcinoma Trial in Tours (Docetaxel, Cisplatin, Fluorouracil)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Docetaxel
- +3 more
-
Tours, FranceHôpital Bretonneau, Service CORad Pôle Henry S Kaplan
Mar 10, 2022
Gastric Adenocarcinoma Trial (Pembrolizumab, Cisplatin, 5-FU)
Completed
- Gastric Adenocarcinoma
- Pembrolizumab
- +4 more
- (no location specified)
Aug 18, 2022
Triple-negative Metastatic Breast Cancer Trial in Boston (Cisplatin, AZD1775)
Completed
- Triple-negative Metastatic Breast Cancer
- Cisplatin
- AZD1775
-
Boston, MassachusettsDana-Farber Cancer Institute
Oct 29, 2021
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic
Recruiting
- Untreated Resectable Pancreatic Adenocarcinoma
- +2 more
- Paclitaxel protein bound
- +3 more
-
Scottsdale, ArizonaHonorHealth Research Institute
May 10, 2022
Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)
Active, not recruiting
- Biliary Tract Neoplasms
- Durvalumab
- +3 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 26, 2021
Esophageal Squamous Cell Carcinoma Trial in Beijing (nab-paclitaxel, Cisplatin, Capecitabine)
Recruiting
- Esophageal Squamous Cell Carcinoma
- nab-paclitaxel
- +2 more
-
Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
Mar 13, 2022
Urothelial Carcinoma of the Urinary Bladder Trial in New York (Cabazitaxel, Gemcitabine, Cisplatin)
Recruiting
- Urothelial Carcinoma of the Urinary Bladder
- Cabazitaxel
- +2 more
-
New York, New YorkColumbia University Medical Center- HIP
Feb 3, 2022
Urinary Bladder Tumors Trial in San Antonio (AGEN1884, AGEN2034, Cisplatin)
Active, not recruiting
- Urinary Bladder Neoplasms
- AGEN1884
- +3 more
-
San Antonio, TexasMays Cancer Center
Mar 11, 2022
Carcinoma, Small Cell Trial in Hwasun (Belotecan, Etoposide, Cisplatin)
Completed
- Carcinoma, Small Cell
- Belotecan
- +2 more
-
Hwasun, Korea, Republic ofChonnam National University Hwasun Hospital
Aug 2, 2021
Muscle-Invasive Bladder Carcinoma Trial in Roma (Nivolumab, Nab paclitaxel, Cisplatin)
Not yet recruiting
- Muscle-Invasive Bladder Carcinoma
- Nivolumab
- +3 more
-
Roma, ItalyRoberto iacovelli
Jan 10, 2022